Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 6/20 | 0.76 |
| ▸ | MC4R | P32245 | 1/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28280920 | 0.88 | CYP2D6 (0.64) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL16226061 | 0.87 | CYP2D6 (1.00) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL6706135 | 0.87 | CYP2D6 (1.00) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL7264542 | 0.87 | CYP2D6 (1.00) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL23850144 | 0.83 | CYP2D6 (0.83) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL7097730 | 0.83 | CYP2D6 (0.83) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL31046801 | 0.83 | CYP2D6 (0.83) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL8983562 | 0.83 | CYP2D6 (0.83) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL8983627 | 0.83 | CYP2D6 (0.83) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL30364156 | 0.83 | CYP2D6 (0.83) | CYP2D6MC4ROPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026110-B | Fused tricyclic compounds as protein kinase inhibitors | 国家公共部门基金会卡洛斯三世国家癌症研究中心(F.S.P.CNIO) | 2022-02-08 | — | — | CN | claimed |
| US-9732061-B2 | Cinnoline derivatives useful as CB-1 receptor inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-15 | — | — | US | claimed |
| WO-2016115013-A1 | CINNOLINE DERIVATIVES USEFUL AS CB-1 RECEPTOR INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-21 | — | — | WO | claimed |
| US-20160200719-A1 | CINNOLINE DERIVATIVES USEFUL AS CB-1 RECEPTOR INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-14 | — | — | US | claimed |
| CN-1984655-A | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-06-20 | — | — | CN | claimed |
| EP-0063365-B2 | 1,4-Dihydropyridine derivative and pharmaceutical composition containing same | KYOWA HAKKO KOGYO KK (JP) | 1994-06-15 | — | — | EP | claimed |
| EP-0063365-B1 | 1,4-DIHYDROPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1985-09-04 | — | — | EP | claimed |
| CN-109526219-A | Benzsulfamide and its purposes as therapeutic agent | 泽农医药公司 | 2019-03-26 | — | — | CN | disclosed |
| US-9732061-B2 | Cinnoline derivatives useful as CB-1 receptor inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-15 | — | — | US | disclosed |
| WO-2016115013-A1 | CINNOLINE DERIVATIVES USEFUL AS CB-1 RECEPTOR INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-21 | — | — | WO | disclosed |
| US-20160200719-A1 | CINNOLINE DERIVATIVES USEFUL AS CB-1 RECEPTOR INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-14 | — | — | US | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-1140852-A1 | 1,2,3,4-TETRAHYDRONAPHTHALENES AND THEIR PHARAMACEUTICAL USE | AstraZeneca AB (SE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035882-A1 | 1,2,3,4-TETRAHYDRONAPHTHALENES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2000-06-22 | — | — | WO | disclosed |
| US-5358949-A | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-25 | — | — | US | disclosed |
| EP-0280873-A1 | Piperidines, medicines containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1988-09-07 | — | — | EP | disclosed |
| EP-0236140-A2 | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
| US-4500452-A | NOT SUBJECT TO ENZYME DEACTIVATION | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1985-02-19 | — | — | US | disclosed |
| US-4472304-A | CARCINOSTATIC | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1984-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200719-A1 | CINNOLINE DERIVATIVES USEFUL AS CB-1 RECEPTOR INVERSE AGONISTS | CNR1, CNR2, GPR119 | CYP2D6 1526/4885MC4R 298/4885OPRM1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.